IQVIA Holdings Hisse Senedi Görünümü: Wall Street Boğa mı yoksa Ayı mı?

IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish?

Fri, August 21, 2026 at 2:40 PM GMT+3 3 min read

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) is a leading global provider of clinical research services, healthcare intelligence, advanced analytics, and technology solutions for the life sciences and healthcare industries. Valued at $41 billion by market cap, the company helps pharmaceutical, biotechnology, and medical-device companies develop, test, and commercialize new treatments by combining vast healthcare data with AI, analytics, and deep industry expertise.

IQVIA has given investors a reason to cheer, outpacing the broader market over the past year. IQV has surged 33.3% over this time frame, outpacing the S&P 500 Index ($SPX) has rallied nearly 19.5% and the Health Care Select Sector SPDR Fund's (XLV) 25.4% return.

More News from Barchart

The momentum has continued into 2026, with IQV up 13.6% year to date, edging past both the SPX's 11.6% rise and XLV's 11.4% gain.

On July 28, IQVIA released its FY2026 earnings, and investors wasted no time cheering the results, with the stock surging 13.9%. Revenue climbed 8.7% year over year to $4.37 billion, surpassing Wall Street's $4.30 billion estimate, while adjusted EPS rose 12.1% to $3.15, beating the $3.03 consensus forecast. The Commercial Solutions revenue increased 8.6% to $1.79 billion and Research & Development Solutions revenue grew 8.8% to $2.58 billion. The quarter was particularly strong on the demand and bookings front. R&DS generated a record $3.15 billion in net new bookings, up 19% year over year, translating to a healthy 1.22x book-to-bill ratio.

Buoyed by the strong execution and improving growth outlook, IQVIA raised its full-year 2026 guidance. The company now expects revenue of $17.28 billion to $17.48 billion, adjusted EBITDA of $4 billion to $4.05 billion, and adjusted diluted EPS of $12.80 to $13.

For fiscal 2026, IQVIA is expected to keep the earnings momentum alive, with analysts forecasting 7% year-over-year growth in diluted EPS to $11.57. The company has also built a solid habit of showing up ahead of market expectations, beating Wall Street's consensus estimates in each of the past four quarters.

Wall Street remains firmly in IQVIA's corner. Among the 20 analysts covering IQV, the consensus rating is a "Strong Buy," backed by 16 "Strong Buy" ratings, one "Moderate Buy," and three "Holds."

The bullish majority remains overwhelming, although sentiment has cooled slightly from three months ago, when the stock had 17 "Strong Buy" recommendations.

On July 2, Baird turned more bullish on IQVIA, raising its price target to $249 from $230 and naming the stock a "Bullish Fresh Pick," while maintaining its "Outperform" rating. The firm sees IQVIA as well positioned to capitalize on the growing adoption of AI in clinical trials, with the company emerging as a key beneficiary of the industry's shift toward more technology-driven and AI-integrated research solutions.

The mean price target of $268.31 represents a 4.8% premium to IQV's current price levels. The Street-high price target of $300 suggests an ambitious upside potential of 17.2%.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com